Frontlight ResearchEarly access
WithdrawnNo phase
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
Key facts
- Who runs it
- University of Oklahoma
- Trial code
- Status
- Withdrawn
- Started
- Jun 2025
- Ended
- 4 Jun 2025
- Type of study
- Interventional
- Treatments tested
- Ecologic Momentary Assessment (EMA)
- Record updated
- 3 February 2026
- Why it stopped
- Study withdrawn due to lack of accrual.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 18 years and older
- Written informed consent and any locally-required authorization obtained from the patients prior to performing any protocol-related procedures, including screening evaluations
- Pathologically (histologically or cytologically) proven diagnosis of cancer of the head and neck (nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, or unknown primary) or Gynecologic cancers (cervical and endometrial)
- Locally recurrent or metastatic HNC or Gyn cancer not deemed amenable to curative-intent salvage therapy, in whom at least six months have passed since their prior RT, if received
- Must have evaluable lesion per RECIST v1.1
- Patients agree to provide their smoking history prior to registration
- ECOG performance status of 0-2
Who cannot take part
- Prior radiotherapy to the region of the study cancer within less than 6 months
- Patients who have received prior radiation therapy and who, in the opinion of the treating radiation oncologist, cannot be reirradiated safely without excess risk of severe toxicity given prior radiation dose to critical structures
- Patients with known contraindications to radiotherapy, including inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., Ataxia-Telangiectasia, Nijmegen Breakage Syndrome)
- Female patients who are pregnant
About the trial
What the trial wants to find out
The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.
The group in the trial
- Ecological Momentary Assessments (EMAs)Other group
Patients will receive one EMA (Ecologic Momentary Assessment) per day for approximately 75 days, through the provided smart phone application.
Treatment: Ecologic Momentary Assessment (EMA)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Quality of Life Assessment of Hypofractionated Radiotherapy in Recurrent Head and Neck Cancer: CPC-CT Pilot
- Record updated
- 3 February 2026